Lymphoma
Brentuximab Vedotin Delivers Clinical Results in Both
Pre- and Post-Transplant Hodgkin Lymphoma
Brentuximab vedotin, an antibody-drug conjugate that targets CD30-positive cells, was the focus of much attention
at the 56th ASH Annual Meeting. Two studies highlighted
the progress that is being made in the care of hard-to-treat
Hodgkin lymphoma patients.
In the first study, Craig Moskowitz, MD, from the Memorial Sloan
Kettering Cancer Center in New York, described unprecedented
results from the large AETHERA trial